<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43354">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01668225</url>
  </required_header>
  <id_info>
    <org_study_id>OVO-11-02</org_study_id>
    <nct_id>NCT01668225</nct_id>
  </id_info>
  <brief_title>Impact of Follicular and Blood G-CSF on Pregnancy and Implantation Rate During Modified Natural in Vitro Fertility Cycle</brief_title>
  <acronym>G-CSF FIVnat</acronym>
  <official_title>Impact of Follicular and Blood G-CSF on Pregnangcy and Implantation Rate During Modified Natural in Vitro Fertility Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OVO R &amp; D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OVO R &amp; D</source>
  <oversight_info>
    <authority>Canada: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, scientists look into G-CSF (Granulocyte - Colony Stimulatin Factor). The use of
      this molecule is increasing in reproduction pathology. High level of follicular and blood
      G-CSF on the day of oocyte retrieval could correlate with higher pregnancy and implantation
      rates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Serum and / or follicular minimum level of G-CSF predictive of pregnancy</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Fertility Diseases</condition>
  <arm_group>
    <arm_group_label>G-CSF FIV nat</arm_group_label>
    <description>Patient following a natural In Vitro Fecondation cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.
Taking the follicular fluid during the oocyte collection day</description>
    <arm_group_label>G-CSF FIV nat</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum sample Follicular fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a natural cycle of an In Vitro Fecondation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 18 and 43 years old

          -  Women natural In Vitro Fecondation

        Exclusion Criteria:

          -  No exclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Lehmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique ovo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Levesque</last_name>
    <phone>(514) 798-2000</phone>
    <phone_ext>755</phone_ext>
    <email>c.levesque@cliniqueovo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Harnois</last_name>
    <phone>(514) 798-2000</phone>
    <phone_ext>755</phone_ext>
    <email>m.harnois@cliniqueovo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ovo Fertilité</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>J4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Brugerie, Director</last_name>
      <phone>(514) 798-2000</phone>
      <phone_ext>753</phone_ext>
      <email>s.brugerie@cliniqueovo.com</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Levesque, Research assistant</last_name>
      <phone>514-798-2000</phone>
      <phone_ext>755</phone_ext>
      <email>c.levesque@cliniqueovo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>June 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
